Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Split Thickness Donor Site Healing With MIST Study

This study has been completed.
Information provided by (Responsible Party):
Celleration, Inc. Identifier:
First received: October 4, 2010
Last updated: December 18, 2014
Last verified: December 2014
Subjects requiring skin grafting due to burns, trauma, or chronic venous ulcers with split thickness donor sites expected to be between 20 and 200 square cm will be consecutively screened for study eligibility. This study is a prospective, randomized, controlled trial evaluating effect of MIST Therapy on the healing of split thickness skin graft donor sites compared to standard care. Subjects meeting all eligibility criteria and providing appropriate written informed consent will be enrolled for study participation.

Condition Intervention
Venous Ulcers
Device: MIST Therapy
Other: Standard of care

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled Pilot Study of the MIST Therapy System for the Treatment of Split Thickness Donor Sites

Resource links provided by NLM:

Further study details as provided by Celleration, Inc.:

Primary Outcome Measures:
  • Rate of Wound Healing [ Time Frame: Days to absence of drainage from the initial donor site harvest procedure ]
    The primary endpoint is an average of the group for each participant's donor site wound closure time, defined as days to absence of drainage from the date of the initial donor site harvest procedure.

Secondary Outcome Measures:
  • Time to Full Epithelialization [ Time Frame: Days to full epithelialization ]
    Time to full epithelialization in days from the date of initial donor site harvest procedure per the blinded adjudication of the donor site image.

  • Numeric Pain Score [ Time Frame: 5 weeks ]
    Average donor site pain score for each treatment group, numeric scale of 0 (no pain) to 10 (worst possible pain), at five weeks post skin graft procedure

  • Numeric Itching Score [ Time Frame: 5 weeks ]
    Average donor site itching score for treatment group, numeric scale 0 (no itch) to 10 (worst possible itch), at 5 weeks post skin graft procedure

  • Donor Site Recidivism Rate [ Time Frame: 6 weeks ]
    Number of donor sites that healed and then reopened during the study.

Enrollment: 32
Study Start Date: February 2012
Study Completion Date: July 2014
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MIST Therapy in conjunction with SOC
Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
Device: MIST Therapy
Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
Other Names:
  • MIST
  • MIST Treatment
Active Comparator: Control arm
Standard of care treatment
Other: Standard of care
Standard of care provided per site-specific protocol
Other Name: Standard wound care

Detailed Description:

Enrolled subjects will be randomized to receive one of two treatment courses: a) MIST Therapy in conjunction with standard of care (SOC) (treatment group); or b)SOC alone (control group).

On post-op day 1, subjects will undergo a baseline evaluation prior to initiating assigned study treatment, including: wound measurement, wound bed evaluation, description of periwound skin, measurement of type and quantity of exudation, wound clinical symptoms (pain, burning, itching), and digital photography. Subject will then receive assigned study treatment.

SOC includes, but is not limited to, fluid resuscitation, pain medications, systemic antibiotics, control of bleeding, and standard dressings as appropriate for the moisture balance of the wound. SOC also includes providing a hydrocolloid border around the wound with a transparent film dressing over the donor site. No advanced or impregnated dressings are allowed during the study. No topical antibiotics or antibiotic dressings, topical antiseptics (silver, iodine, etc.,) or antimicrobials are allowed.

The transparent film will be removed each day and wound fluid will be collected for analysis. After wound fluid collection, subjects will receive their assigned study treatment. Subjects randomized to receive MIST Therapy will be treated daily for 5 consecutive days. Following administration of the assigned study treatment, subjects will have replacement of the transparent film. The hydrocolloid will remain in place on the border of intact skin.

Evaluations performed will include a wound assessment, digital photography, wound pain assessment and an adverse event assessment. Following the initial 5 day treatment, the study wounds will be dressed per SOC with dressing changes as needed.

Subjects will undergo a weekly wound assessment through 6 weeks from the date of study enrollment. A weekly wound assessment will include the assessment of maintained wound closure, digital photography, and an adverse event assessment.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subject of any race and at least 18 years old
  • Subject requires skin grafting
  • Subject's wound must be between 20 cm2 and 200 cm2
  • Subject's wound presents with no clinical signs of acute infection
  • Subject has ahd no prior MIST Therapy to the enrolled wound
  • Subject or subject's legally authorized representative understands the nature of the procedure(s) and provides written informed consent prior to study enrollment
  • Subject is willing and able to comply with all specified care and visit requirements
  • Women of childbearing potential must not be pregnant or lactating, and must be using adequate and accepted contraceptive methods
  • Subject has a reasonable expectation of completing the study

Exclusion Criteria:

  • Subject's condition requires the use of topical antibiotics at the time of study enrollment
  • Subject's wound would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the subject is using a cardiac pacemaker
  • Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements
  • Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01214980

United States, Florida
Tampa General Hospital
Tampa, Florida, United States, 33606
Sponsors and Collaborators
Celleration, Inc.
Principal Investigator: Lisa J Gould, M.D.,Ph.D James A. Haley Veterans Hospital
Principal Investigator: David Smith, MD University South Florida
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Celleration, Inc. Identifier: NCT01214980     History of Changes
Other Study ID Numbers: CR-86003
Study First Received: October 4, 2010
Results First Received: December 11, 2014
Last Updated: December 18, 2014

Keywords provided by Celleration, Inc.:
Low-frequency ultrasound
Wound healing
Split thickness wound healing
Skin graft donor site healing

Additional relevant MeSH terms:
Varicose Ulcer
Varicose Veins
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases processed this record on April 28, 2017